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Introduction
Effective treatment strategies for relapsed hepato-
cellular carcinoma (HCC) are largely missing and 
the vast majority of patients succumb to the dis-
ease. In recent years, some new therapeutic strate-
gies in addition to sorafenib, have been approved 
for patients with HCC.1 Unfortunately, the cur-
rent strategies have only very limited effects in 
prolonging overall survival in HCC and novel 
treatments are needed. As cancer often harbors 
genetic instability and an elevated level of DNA 
damage, they are often addicted to effective DNA 
repair. Hence, targeting DNA repair should be a 
viable strategy exploited in the clinic to target can-
cer.2 Here, we wanted to test whether inhibition of 
DNA repair may provide a promising opportunity 
for cancer treatment including for HCC.
Oxidative stress is a common pathogenic feature 
in hepatitis B virus (HBV) infection, hepatitis C 
virus (HCV) infection, or other precancer con-
ditions leading to HCC as well as in HCC pro-
gression.3 HCV-associated HCC exhibits a high 
level of oxidative stress, even in the absence of 
inflammation.4 Although the underlying molec-
ular mechanism is not entirely clear, it has been 
demonstrated that the HCV core protein induces 
mitochondrial injury and oxidative stress,5 which 
may be related to its ability to inhibit deoxy-
cholic acid-mediated apoptosis.6 Altered redox 
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regulation has been reported to contribute to 
hepatocarcinogenesis owing to the redox-medi-
ated mutagenesis of critical cellular genes. The 
marker for oxidative stress, 8-oxo-2c-deoxy-
guanosine (8-oxo-dG), is increased in HCC and 
has been positively correlated with HCC grades7,8 
Moreover, high levels of 8-oxo-dG in noncancer-
ous regions also predicted an increased risk of 
tumor recurrence in patients with HCC.9 
However, dysfunctional redox regulation and an 
increased reactive oxygen species (ROS) tension 
can also cause oxidative damage to DNA directly, 
or to free bases in the cellular and mitochondrial 
deoxynucleoside triphosphate (dNTP) pool.10,11
The MTH1 protein is involved in the main defense 
to oxidative stress and prevents oxidized dNTPs, 
for example, 8-oxo-dGTP or 2-OH-dATP, from 
being incorporated into DNA.12,13 Interestingly, 
the MTH1 protein is nonessential in nontrans-
formed cells and MTH1 knockout mice live and 
grow old,14 which altogether suggest that oxidative 
stress levels are kept low in normal cells. 
Interestingly, we and others found that MTH1 
enzyme is required for survival of cancer cells as a 
likely result of high levels of oxidative stress in can-
cer.15–19 Furthermore, we have developed small 
molecule MTH1 inhibitors that are selectively 
toxic to cancer cells while sparing normal cells. 
Karonudib (TH1579) supports clinical investiga-
tion of MTH1 inhibitor with excellent pharma-
cokinetic and pharmacodynamics properties.15,20
Here, we evaluate if the high level of oxidative 
stress in HCC renders the carcinoma addictive to 
MTH1. We study MTH1 levels in HCC tissue, 
the toxicity of MTH1 siRNA and inhibitors and 
the potential therapeutic effects of MTH1 inhibi-
tors in vivo.
Material and methods
Sample information
All samples were collected in Department of Liver 
Surgery, Renji Hospital, Shanghai Jiaotong 
University School of Medicine. Fresh samples, 
including tumor tissues and portal vein tumor 
thrombus (PVTT), were obtained from HCC 
patients during tumor resection. Normal livers 
were collected from healthy liver donors during 
liver transplantation. A total of 123 HCC tumor 
samples were used to generate a second HCC tis-
sue microarray cohort. All samples were Asian 
HCCs. The median age of this cohort of patients 
was 50 years (range 17–78 years). The majority of 
patients were HBV-positive (106/123). Patient 
samples from healthy liver donors and HCC 
patients undergoing tumor resection were obtained 
following informed consent for this study, and 
the protocol was approved by the ethical review 
committee of the World Health Organization 
Collaborating Center for Research in Human 
Production (authorized by the Shanghai Municipal 
Government) and the Ethics Committee of Renji 
Hospital, School of Medicine, Shanghai Jiao Tong 
University (#2017-001). The present research was 
carried out according to the provisions of the 
Helsinki Declaration of 1975. No organs from exe-
cuted prisoners were used in the present study.
Immunohistochemistry stain and analysis
All tissue samples were fixed in phosphate buff-
ered neutral formalin and routinely embedded in 
paraffin, and then cut into 4 μm thick sections. 
The sections were detected with primary anti-
body for MTH1 overnight at 4°C. After incuba-
tion with a suitable second antibody, the sections 
were treated with diaminobenzidine and counter-
stained with hematoxylin. To quantify the level of 
MTH1 protein expression, all the sections were 
observed and photographed with a microscope 
(Carl Zeiss) and scored according to the ratio and 
intensity of positive staining cells: 0–5% scored 0; 
6–35% scored 1; 36–70% scored 2; 70–100% 
scored 3. The final expression level of MTH1 was 
designated as low or high group: score 0–1, low 
expression; 2–3, high expression. These scores 
were determined independently by two experi-
enced pathologists in a blinded manner.
Patient cohorts and statistical analysis
RNA expression profiles generated by the Agilent 
microarray platform for 377 HCC patients and 
paired tumor/paratumor tissue were extracted 
from The Cancer Genome Atlas (TCGA) inter-
face (http://tcga-data.nci.nih.gov/). Of the 
patients, 187 were white, 161 were Asian, 17 were 
black or African American, 2 were American 
Indian or Alaska native, and 10 were not reported. 
The tumor node metastasis (TNM) staging, histo-
logic grade, and the prognostic data of the patients 
were obtained from the clinical supplements in the 
TCGA database. The HCC patients were strati-
fied into two groups with the high and low MTH1 
expression, based on the median MTH1 mRNA 
expression levels in the TCGA database. The 
Clinical outcome between groups was compared 
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using Kaplan–Meier analysis followed by two-
sided log-rank tests (SPSS version 22, IBM 
Software). Multivariate cox regression (SPSS) 
was used to generate influence factors and their 
hazard ratios and 95% confidence intervals (CIs).
Antibodies
The following antibodies were used: rabbit anti-
MTH1 (ab197028, Abcam), rabbit anti-53BP1 
(A300-272A, Bethyl Laboratories), mouse anti-
ATM pS1981 (sc47739, Santa Cruz Biotech), 
rabbit anticleaved PARP1 (9541, Cell Signalling 
Technologies), rabbit anticleaved caspase 3 
(9661s, Cell Signaling Technologies), rabbit anti-
H2AX (05-636, Millipore), and mouse anti-E-
actin (Sigma Aldrich).
Quantitative real-time polymerase chain 
reaction and Western blot
A standard TRIzol method (Invitrogen) was used 
to extract total RNA from tissues and cultured 
cells and to synthesize complementary DNA. 
Quantitative real-time polymerase chain reaction 
(RT-qPCR) was performed using SYBR Premix 
Ex Taq (Takara) in an ABI PRIS 7900HT 
sequence detector. The beta-actin gene was used 
as an endogenous control. The primer sequences 
were as follows: beta-actin forward: 5c-CCTG 
GCACCCAGCACAAT-3c, beta-actin reverse: 
5c-GGGCCGGACTCGTCATACT-3c, MTH1 
forward: 5c-GTGCAGAACCCAGGGACCAT-3c, 
MTH1 reverse: 5c-GCCCAC GAACTCAAACA 
CGA-3c. Liver tissue or HCC cell line extracts 
were prepared for immunoblotting analyses, as 
described previously.21,22 Immunoblots were 
probed with antibodies against the related anti-
bodies at the recommended dilutions.
Cell culturing and cellular assays
Human HCC cell lines Hep3B and C3A cells 
were originating from ATCC and were cultured in 
MEM. Human HCC cell lines SMMC-7721, 
MHCC-97L, and MHCC-97H were all preserved 
at the Shanghai Cancer Institute, Ren Ji Hospital, 
School of Medicine, Shanghai Jiao Tong 
University and were cultivated in Dulbecco’s 
modified Eagle medium (DMEM) supplemented 
with 10% (v/v) fetal calf serum at 37°C in a 
humidified incubator under 5% CO2 condition. 
Cell viability was measured with Resazurin assay, 
clonogenic outgrowth assays. To determine the 
effect of MTH1 silencing on cell viability, 1000 
cells were seeded onto 10 cm well plates with a 
mixture of transfection agents and nontarget 
siRNA control or MTH1 siRNA (10 nM). Culture 
media was replaced 24 h later and incubated at 
37°C, 5% CO2 condition for another 10 days. 
The modified comet assay with OGG1 detecting 
8-oxo-dG lesions in DNA and immunofluores-
cence were performed as described previously.15
Immunofluorescence
Cells were seeded on coverslips in 24-well plates 
(10,000–15,000 cells per well) for observation 
with confocal microscopy. The cells were treated 
with compounds the next day. Cells were fixed with 
3% paraformaldehyde in phosphate-buffered saline 
(PBS; pH 7.5) with 0.1% Triton X-100 for 15 min 
at room temperature. Samples were permeabilized 
with 0.3% Triton X-100 in PBS and blocked in 
3% bovine serum albumin (BSA), 0.1% Tween 
20 in PBS. Primary and secondary Alexa-Fluor-
conjugated antibodies were diluted in 3% BSA, 
0.1% Tween 20 in PBS. DNA was counterstained 
with DAPI (Invitrogen). Images were acquired in 
a Zeiss LSM-510 confocal microscope with the 
488 oil objective. For high-throughput immuno-
fluorescence, cells were seeded in 96-well plates 
(2500–3000 cells per well). The cells were treated 
with compounds the next day. Cells were fixed 
and stained as described above. DNA was coun-
terstained with DAPI. Quantification was done by 
automatic acquisition of images (500 cells per well) 
using the In Cell Analyzer 2000 (GE Healthcare) 
and Developer software (GE Healthcare).
Transfections
For siRNA transfections, cells were seeded at 20–
40% confluency and transfected with 10 nM 
siRNA and INTERFERin (Polyplus Trans-
fections) the next day according to the manufac-
turer’s protocol. Cells were transfected in media 
without PeSt. For NT RNA control, the All-stars 
negative control (Qiagen) was used. The siRNA 
sequences used were as follows: MTH1 siRNA 
#1 GACGACAGCUACUGGUUUC; MTH1 
siRNA #2 GAAAUUCCACGGGUACUUC; 
MTH1 siRNA #3 CGACGACAGCUACUG 
GUUU. Stable cell lines were made by transfect-
ing cells with plasmid DNA and JetPEI (Polyplus 
Transfections) according to the manufacturer’s 
protocol. Cells were selected using 600 µg/ml 
G418 (MutT-myc vector) for 2 weeks before 
 single-cell clones were isolated. Overexpression 
was verified by Western blot. Bacterial expression 
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constructs were performed as described previ-
ously.15 Overexpression of H2B-GFP in Hep3b 
cells was established by lentiviral transfection of 
H2b-GFP pLenti-CMV-hygro plasmid and selec-
tion with 200 µg/ml hygromycin for 7 days.
Time-lapse video microscopy
For time-lapse microscopy, we used Hep3B cells 
stably expressing H2b-GFP. Hep3B H2b-GFP 
cells were seeded a 96-well plate and the next day 
treated with 500 nM Karonudib or DMSO alone. 
Images were acquired in the GFP channel every 
5 min for 24 h using an ImageXpress MicroXL 
(Molecular Devices) microscope. Cells were kept 
at 37°C with 5% CO2 and the acquisition started 
after 30 min from the addition of the compounds. 
Stacked images were analyzed using the ImageJ 
software. Quantification was performed by fol-
lowing individual cells (25 cells/sample) over time 
and scoring for time in interphase and mitosis as 
well as mitotic defects and the outcome of cell 
division [normal G1, mitotic slippage/polynuclea-
tion (MS/PN), aneuploidy, mitotic slippage 
(MS), bridges, and death in mitosis (DiM)].
Xenograft study
All animals studies were performed in compli-
ance with EU 2010/63 directive on the protec-
tion of animals used for scientific purposes and 
Animal Scientific Procedures Act 1986 and 
approved by regional animal ethical committee 
in Stockholm (#N584/11, N2/11, N89/14). All 
animals were acclimatized for at least 7 days 
before initiation of study. The laboratory animals 
had free access to water and food as well as 
enrichment. The temperature, humidity, light 
cycle, and cage size were according to laboratory 
animal guidelines and regulations. The animals 
were housed 3–5 mice per cage. The group size 
was based on previous experience of MTH1 
inhibitor and disease model (n = 6–8/group). The 
exclusion/inclusion criteria was predefined in 
ethical license as was the human end point (0.6p 
according to Karolinska Institutet scoring for 
animal health) and maximal tumor burden was 
set as 1000 mm3. Tumor volume was measured 
at least twice weekly by using an electrical caliper 
and calculated as length × width × width × 0.52. 
Body weight was measured twice weekly and the 
general status of the treated animals were checked 
daily. NOD-SCID mice (5–6 weeks, male and 
female, local breeder Karolinska Institutet, 
Sweden) were used in the HepB3 xenograft 
model. Cancer cells (1 × 106 Hep3B cells) were 
diluted in Matrigel (1:1, BD Bioscience) and 
injected subcutaneously in the sacral area of the 
mice. When tumor reached approximately 
100 mm3, the animals were randomized into the 
various groups and treatment initiated (baseline 
average ± SD tumor size and body weight, respec-
tively; vehicle group, 82 ± 26 mm3, 21 ± 3 g, n = 8; 
Karonudib group, 78 ± 13 mm3, 23 ± 4 g, n = 8; 
sorafenib group, 79 ± 12 mm3, 21 ± 3 g, n = 6). 
Karonudib and sorafenib were diluted in 5% 
DMSO, 10% Cremaphore, 10% Tween 80, and 
75% water, and pH adjusted with acetic acid 
(1M) to pH 4.5–5.0. Control animals obtained 
vehicle with 5% DMSO, 10% Cremaphore, 10% 
Tween 80, and 75% water, and pH adjusted to 
4.5–5. Karonudib (90 mg/kg b.i.d., p.o.) or vehi-
cle was administrated Monday, Wednesday, and 
Friday and sorafenib (30 mg/kg q.d., p.o.) was 
administrated daily. All the mice were treated for 
a maximum allowable period of 6 weeks.
Statistical analysis
The quantitative data were compared between 
groups using the one-way and two-way analysis of 
variance (ANOVA). The cumulative survival rates 
were determined using the Kaplan–Meier method 
and log-rank test. The Cox proportional hazards 
model was used to determine the independent fac-
tors that influence survival. A value of p < 0.05 
was considered to be significant. All the analyses 
were performed using the SPSS software (version 
18.0). For the in vivo xenograft study, two-way 
ANOVA with repeated measures and the 
Bonferroni test were used for statistical analysis.
Results
MTH1 levels are upregulated in pathologically 
verified HCC tissue as compared with 
noncancer hepatic tissue
Given the high levels of oxidative stress reported 
in HCC, we wanted to determine whether this 
results in corresponding high levels of MTH1 
protein levels, as a defense mechanism to coun-
teract the oxidative stress. First, we investigated 
the localization and expression of MTH1 in liver 
in surgical specimens obtained from HCC 
patients. Following pathological evaluation, a 
higher MTH1 expression level was detected in 
the HCC and tumor thrombus tissues as com-
pared with that in the normal liver and paracan-
cerous tissues. In the normal liver and 
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paracancerous tissues, MTH1 was mainly 
expressed in macrophages and proliferative bil-
iary tracts but not in hepatocytes (Figure 1A). To 
determine whether the increased MTH1 protein 
level was also reflected by a corresponding 
increase in gene expression, we isolated RNA 
from the specimen and determined MTH1 
mRNA levels by RT-qPCR. Elevated mRNA 
Figure 1. MTH1 expression in liver tissues. (A) Immunostaining of MTH1. The black arrows indicate 
inflammatory cells, and the white arrows indicate proliferated biliary tracts. (B) Relative mRNA expression 
of MTH1 (***p < 0.001). (C) Western blot analysis of MTH1. (D) Kaplan–Meier analysis indicated statistically 
significantly shorter survival of patients in the MTH1 high expression group than the low expression group. P 
refers to paracancerous liver tissues and H refers to HCC tissues (*p < 0.05, **p < 0.01, ***p < 0.001).
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gene expression of MTH1 was observed in can-
cerous tissues as compared with paracancerous 
tissues and correlated with the corresponding 
protein levels observed (Figure 1B and C). The 
results demonstrate upregulation of MTH1 in 
HCC tissue, which suggest that MTH1 may play 
an important role during HCC development.
MTH1 levels are associated with adverse 
biological behaviors of HCC and indicates poor 
prognosis
To further investigate the clinical significance of 
MTH1 expression in HCC, we examined the cor-
relation between the MTH1 expression status 
and clinicopathological characteristics of 123 
HCC patients who were divided into two groups: 
the high expression group (n = 79) and the low 
expression group (n = 44). The results indicated 
that high levels of MTH1 was significantly associ-
ated with adverse clinicopathological parameters 
of HCC, including serum alpha fetoprotein 
(AFP), vascular invasion, histologic grade, and 
TNM stage (Table 1). Moreover, Kaplan–Meier 
survival analysis in the 123 patients with follow 
up demonstrated a poor survival in patients with 
high MTH1 expression (Figure 1D).
Next, we analyzed the expression pattern of 
MTH1 in the TCGA cohort. The results verified 
the higher expression of MTH1 in cancerous tis-
sue compared with paracancerous liver tissue and 
that MTH1 is associated with adverse biological 
behaviors of HCC (Figure 2A–D). Moreover, 
multivariate cox analysis showed MTH1 level, 
TNM staging or histologic grade is correlated 
with the poor prognosis of HCC patients 
(Figure 2E).
HCC cells require MTH1 for survival
These results suggest that HCC is highly depend-
ent on MTH1 for their survival. To investigate 
whether MTH1 could be a target for HCC treat-
ment, we depleted MTH1 using three different 
short interfering RNAs (siRNAs) in two HCC 
different cell lines, resulting in reduced clono-
genic survival and viability in colony formation 
assay (Figure 3A). To determine whether a simi-
lar response could be obtained using the MTH1-
specific inhibitor Karonudib, we treated the five 
different HCC cell lines with increasing concen-
trations of Karonudib (Figure 3B and C). The 
results show that all HCC cell lines are sensitive 
to MTH1 inhibition in both in the colony 
formation assay and the resazurin viability assay, 
indicating that Karonudib is a potential treatment 
for HCC.
Karonudib treatment induces incorporation of 
8-oxo-dG in HCC cancer cells
Previously, it was demonstrated that Karonudib 
treatment results in elevated levels of 8-oxo-dG in 
DNA, which could be reversed by overexpression 
of MTH1, treatment with antioxidants, or more 
elegantly overexpression of the bacterial 8-oxo-
dGTPase MutT fused to nuclear and mitochon-
drial localization signals.20 Here, we confirm 
Karonudib significantly increases the level of 
8-oxo-dG in DNA also in Hep3B cells and that 
overexpression of the bacterial homologue to 
MTH1, MutT, reversed the Karonudib-induced 
elevation of 8-oxo-dG in DNA (Figure 4A and 
B). Next, we observed Karonudib-induced DNA 
damage (53BP1 foci, ATM, cleaved PARP), and 
apoptosis (cleaved Caspase-3) (Figure 4C–E). 
Furthermore, Karonudib treatment caused a 
block in mitosis (Figure 4F–H) and defects in 
chromosome congression causing aneuploidy as 
well as mitotic slippage and polynucleation (MS/
PN), indicating a mitotic defect during prometa-
phase (Figure 4F–H).
In vivo activity of Karonudib
Next, we evaluated the efficacy of Karonudib in 
comparison with Sorafenib, an approved and 
widely used treatment for HCC patients. In 
NOD-SCID mice, Hep3B cancer cell xenografts 
were treated with sorafenib, Karonudib, or vehi-
cle alone: only Karonudib showed significant 
tumor growth inhibition, while sorafenib treat-
ment alone was not effective in delaying tumor 
growth (Figure 5A). Karonudib was well toler-
ated without body weight loss (Figure 5B). Our 
results confirmed previous findings that 
Karonudib effectively inhibited tumor progres-
sion in xenograft mice.20 Karonudib treated 
tumor-bearing mice had significantly longer sur-
vival time before tumor volume reached the cut 
off size of 1 cm3 (Figure 5C).
Discussion
To date, no anticancer treatment has generated 
satisfactory clinical outcomes in HCC patients. 
In the pursuit of novel targeted drugs, we report 
that the MTH1 inhibitor Karonudib can signifi-
cantly suppress the proliferation of HCC in vitro 
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Table 1. Clinicopathological correlation of MTH1 expression in 123 HCC patients using Pearson’s χ2 test.
Variable MTH1
High (n) Low (n) p
Age ⩽50 years 30 16 1.000
>50 years 49 28
Gender Female 15 9 1.000
Male 64 35
Liver Cirrhosis Yes 72 38 0.542
No 7 6
Local infiltration Yes 8 3 0.744
No 70 41
Tumor multiplicity Single 53 36 0.095
Multiple 26 8
Serum AFP ⩽20 ng/ml 20 20 0.028
>20 ng/ml 59 24
Tumor Satellite Yes 9 6 0.777
No 70 38
Tumor differentiation I 1 2 0.040
II 45 33
III 33 9
Vascular invasion Yes 38 9 0.003
No 41 35
Tumor size <5 cm 30 22 0.253
>5 cm 49 22
TNM stage I 30 28 0.028
II 14 7
III 32 9
AFP, alpha fetoprotein; HCC, hepatocellular carcinoma; TNM, tumor node metastasis.
and in vivo by causing incorporation of 8-oxo-
dGTP into DNA, mitotic arrest, and DNA 
damage.
Previously, MTH1 has been reported to be essen-
tial for survival in some types of tumor.18,23–25 In 
this study, we found MTH1 was overexpressed in 
HCC tissue compared with paracancerous or 
normal liver tissues and the elevated expression of 
MTH1 correlated with poor prognosis in HCC 
patients. The high expression of MTH1 in the 
microvascular thrombus in HCC tissues indicates 
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8 journals.sagepub.com/home/tam
that MTH1 may play an important part in HCC 
intrahepatic and remote metastasis and influences 
the long-term survival of HCC patients. When we 
compared our results of MTH1 expression in 
tumor and paired paratumor tissue both in our 
HCC tissue microarray cohort and the TCGA 
database, we found that MTH1 expression was 
increased with the progression of tumor tissue 
(increased TNM staging and histological stag-
ing). Therefore, the role of MTH1 may become 
more critical as the tumor progresses to advanced 
stages. In addition, MTH1, as an independent 
predictor, was correlated with the adverse overall 
survival of HCC patients. The results from clini-
cal samples and the TCGA database suggest that 
inhibition of MTH1 could be a promising thera-
peutic target for treatment of HCC.
Previously, we validated MTH1 as an anticancer 
target and developed TH287 and TH588 as first-
in-class Nudix hydrolase family inhibitors that 
potently inhibit the tumor progression in mela-
noma and breast cancer.15 Concurrently it was 
demonstrated that (S)-crizotinib could induce 
DNA damage and therefore suppress tumor pro-
liferation in colon cancer via MTH1 inhibition.16 
However, in 2016, other studies questioned the 
validity of MTH1 as a target and described con-
troversial results showing MTH1 inhibitors that 
failed to kill cancer cells.26–28 Since then, there has 
been a debate about the role of MTH1 in cancer 
and potential off-targets of MTH1 inhibitors that 
may explain the cytotoxic discrepancy of the vari-
ous published chemical series. Here we used a 
siRNA approach to demonstrate MTH1 is 
Figure 2. MTH1 expression in hepatocellular carcinoma (HCC) in The Cancer Genome Atlas (TCGA) database. 
(A) Relative mRNA expression of MTH1. (B) Kaplan–Meier analysis of overall survival for the expression of 
MTH1. (C, D) MTH1 expression in different tumor node metastasis (TNM) stages and histologic grades. (E) 
Multivariate Cox analysis for the survival of HCC patients (*p < 0.05, **p < 0.01, ***p < 0.001).
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critical for HCC cancer cell survival. This is in 
line with previous MTH1 knockdown results 
reported by us and others,15,20,29–31 as well as with 
the finding that CRISPR-Cas9 depletion of 
MTH1 in a human ovarian cancer xenograft 
model significantly reduced tumor growth and 
cell proliferation.25 Recently, a new small mole-
cule, SB2001, was identified by a phenotypical 
screen in human cervical cancer and shown to be 
cytotoxic. The effect was demonstrated to be 
mediated by a combination of MTH1 inhibition 
and inhibition of LTA4H leading to increased 
oxidative DNA damage.32
We have previously shown that the problem 
underlying the noncytotoxic MTH1 inhibitors 
lies in its failure to increase the DNA-incorporation 
of oxidized nuclear bases20 and that this in turn 
may be due to these compounds’ inability to 
cause a mitotic arrest.33 Karonudib, which in this 
study showed cytotoxic effects on HCC cells 
lines, significantly increased the accumulation of 
8-oxo-dG into DNA in HCC cancer cells. 
Moreover, overexpression of MutT (the bacterial 
MTH1 homolog) rescued the 8-oxo-dGTPase 
activity of MTH1 in HCC cancer cells treated 
with Karonudib. Theoretically, the incorporation 
of toxic dNTPs into the nuclear DNA could 
cause irreversible DNA damage, leading to the 
ultimate cell death.2,34 Our experiments showed 
that treatment with Karonudib resulted in accu-
mulation of nuclear 53BP1 foci and elevated 
expression of ATM and γH2AX, indicating the 
existence of DNA double-strand breaks (DSBs) 
and DNA damage. Karonudib treatment also 
prolonged the time in mitosis followed by aneu-
ploidy, indicating a mitotic defect during 
prometaphase.
While we have demonstrated that Karonudib 
introduces 8-oxo-dG into DNA, DNA damage, 
and mitotic arrest, this study does not specifically 
address the mechanism of action of Karonudib, 
which appears to be more complex than described 
previously.20 Our recent data suggests a dual 
mechanism of action of Karonudib: (i) distur-
bance of microtubule polymerization causing a 
mitotic arrest and (ii) increased incorporation of 
oxidized nucleotides, such as 8-oxo-dG, into 
DNA, resulting in DNA damage and cancer cell 
Figure 3. MTH1 is required for hepatocellular carcinoma (HCC) cancer cell survival. (A) Clonogenic survival 
of Hep3B and C3A cells transiently transfected with MTH1 siRNA (M) or non-targeting siRNA (NT); (B) 
Viability of HCC cells after 72 h Karonudib treatment; (C) Colony counts of HCC cells after 72 h Karonudib 
treatment. Values represent percentage of colonies in relation to DMSO-treated controls. Data shown as 
average ± standard error of the mean of at least two independent experiments.
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Figure 4. MTH1 inhibitor Karonudib causes hepatocellular carcinoma (HCC) cancer cell DNA damage. (A) 
Hep3B cells overexpressing MutT or with no overexpression (vector) were treated with 1 µM Karonudib for 24 h 
before being incubated with OGG1, to selectively cut out 8-oxodG from DNA, and run in alkaline Comet assay. 
(B) Quantification of comet tail moment. Data shown as average ± standard error of the mean (SEM) of at 
least two independent experiments (⩾200 cells per sample size) (***p < 0.001, one-way analysis of variance). 
(C) Induction of 53BP1 foci in Hep3B cells treated with Karonudib for 72 h. (D) Quantification of 53BP1 foci 
formation in Hep3B cells after Karonudib treatment for 72 h. Data shown as average ± SEM of at least two 
independent experiments. (E) Western blot analysis of Hep3B cells treated with increasing concentrations 
of Karonudib (0, 200, 500, and 1000 nM). (F–H) Hep3B cells treated with Karonudib show prolonged time in 
mitosis. (F) The mitotic progression was analyzed with time-lapse microscopy for Hep3B H2B-GFP cells 
and mitotic defects and the outcome of cell division [normal G1, mitotic slippage/polynucleation (MS/
PN), aneuploidy, mitotic slippage (MS), bridges, and death in mitosis (DiM)] were scored. Acquisition was 
started 30 min after addition of 500 nM Karonudib and images were acquired for 20 h; (G) Data shows time in 
mitosis from one representative experiment from 25 cells per condition. The experiment was repeated twice 
with similar results (*p < 0.05, Student’s t test). (H) Representative time-lapse images showing the mitotic 
progression. Note the congression defect (arrowheads) and micronuclei (arrows) after Karonudib treatment. 
Numbers indicate time in minutes. Scale bar: 10 µm.
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death.33 More detailed mechanistic studies fall 
beyond the scope of this current manuscript and 
are addressed separately.33
In our in vivo study, Karonudib was more effec-
tive in slowing down Hep3B tumor progression 
compared with sorafenib. Although sorafenib is 
currently the standard therapy for HCC patients, 
the efficiency is not satisfactory and the side 
effects, especially diarrhea and weight loss, are a 
severe problem in the clinic.35 Here, we used a 
dose of 30 mg/kg sorafenib, a treatment that was 
reported to show a better survival with fewer side 
effects.36 Similar to some previous studies, 
sorafenib treatment had only marginal antitumor 
efficacy in the mouse Hep3B xenograft model, 
especially in the early stages of tumor progres-
sion.36–38 Interestingly, although a population of 
cells seems to be resistant to Karonudib treat-
ment in vitro, Karonudib treatment significantly 
reduced Hep3B xenograft tumor growth. Indeed, 
Karonudib treated mice showed better survival 
compared with sorafenib- or vehicle-treated ani-
mals. Our results indicated that Karonudib may 
serve as a potential drug candidate for the treat-
ment of liver cancer.
In conclusion, we have described MTH1 as an 
independent prognosticator of HCC patient sur-
vival and a novel molecular target in HCC devel-
opment and therapy. The MTH1 inhibitor 
Karonudib potently kills HCC cancer cells both 
in vitro and in vivo. Therefore, Karonudib is a 
promising anti-HCC drug. These findings 
strongly suggest that more preclinical studies and 
clinical trials should be conducted to evaluate the 
efficacy of MTH1 inhibitors in preventing HCC 
progression.
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